Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

n Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy of SNS-595, SNS-032 and SNS-314, planned additional clinical testing and development efforts, the timing of enrollment in clinical trials and the announcement of clinical results. Words such as "look forward," "suggests," "may," "expects," "designed," "believe," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities, including enrollment and reporting of results, could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for SNS-595, SNS-032 and/or SNS-314 may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials and manufacturing of SNS-595, SNS-032 and SNS-314 and risks related to Sunesis' need for additional funding. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' annual report on Form 10-K for the year ended December 31, 2006 and other filings with the Securities and Exchange Commission.
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Pearl's Premium Ultra Low ... drought tolerant grass seed this week with the release ... announcement coincides with the fact that it is time ... many believe. , As of the date 6/4/13, ... reviews by industry experts and the media including: ...
(Date:9/22/2014)... tiny cell fragments whose job it is to stop ... nucleus. But they can "feel" the physical environment around ... , Platelets respond to surfaces with greater stiffness by ... on" other platelets and other components of the clotting ... we give them credit for, in that they are ...
(Date:9/22/2014)... create a highly sensitive chemical sensor based on the ... electronic properties that the researchers were able to exploit ... times. , The study is available online in advance ... Salehi- Khojin, asst professor of mechanical and industrial engineering ... Bijandra Kumar, post doc where they are doing research ...
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 ... their suffering, restoring hope an quality of life and ... possible because of the innovative cellular biomedicines research that ... reality. , The company was founded in 1994 ... (president, chief of research, and Topricin inventor), Aurora Paradise ...
Breaking Biology Technology:Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6
... insiders knowingly misrepresented the ... company ... Shapiro filed a,proposed class-action lawsuit on behalf of CellCyte Genetics ... company and chief executive officer Gary A.,Reys, background, causing company ...
... Jan. 18 Brinks Hofer Gilson & Lione, one ... States, is,pleased to announce that 21 of its attorneys ... survey conducted by Law & Politics magazine.,Additionally, 11 Brinks ... Martin Addy, chair of the Appellate Group at Brinks, ...
... Record 20 Million Signatures Collected on myLifetime.com in ... Bipartisan Breast Cancer Patient Protection Act Allows Women Choice to, Recuperate ... ... Cancer Surgery -, NEW YORK, Jan. 18 "Desperate ...
Cached Biology Technology:Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3Twenty-One Brinks Hofer Gilson & Lione Attorneys Named 2008 'Illinois Super Lawyers' 2Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross to Join Lifetime Networks and Members of Congress From Both Parties at Capitol Hill Press Conference 2Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross to Join Lifetime Networks and Members of Congress From Both Parties at Capitol Hill Press Conference 3
(Date:9/21/2014)... (SACRAMENTO, Calif.) Mothers of children with autism are significantly ... during their pregnancies than the mothers of children who ... UC Davis MIND Institute has found. , Low iron ... autism in the child if the mother was 35 ... or if she suffered from metabolic conditions such as ...
(Date:9/21/2014)... In recent years, new strains of bacteria have emerged ... these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, ... at least 23,000. Despite the urgent need for new ... antibiotics in the past decade. , MIT engineers have ... Using a gene-editing system that can disable any target ...
(Date:9/19/2014)... Call it the Jimmy Durante of dinosaurs ... nasal profile. The new dinosaur, named Rhinorex ... University and Brigham Young University, lived in what ... during the Late Cretaceous period. , Rhinorex, which ... and a close relative of other Cretaceous hadrosaurs ...
Breaking Biology News(10 mins):Mothers of children with autism less likely to have taken iron supplements 2Battling superbugs 2Battling superbugs 3Battling superbugs 4New hadrosaur noses into spotlight 2
... to the evolutionary puzzle to explain why certain mammal families ... In research published in Proceedings of the Royal Society ... Dr Alistair Evans proposed a new theory explaining the diversity ... around two grams, to the blue whale which clocks in ...
... June 24, 2013 /PRNewswire-iReach/ -- Strax Rejuvenation, one of the ... just announced a "Get Ready for Summer" promotion that features ... (Photo: http://photos.prnewswire.com/prnh/20130624/CG36984 ) For ... syringe instead of the usual price of $550; and Radiesse ...
... from a rare metabolic complication during pregnancy are programmed to ... Journal of Clinical Investigation . The study is ... babies born to mothers with intrahepatic cholestasis of pregnancy (ICP), ... by the build-up of bile acids in the bloodstream. ...
Cached Biology News:From minute to massive -- mammal size evolution explained 2Non-Surgical Procedures are Now Available at a Discount at Strax Rejuvenation 2Non-Surgical Procedures are Now Available at a Discount at Strax Rejuvenation 3Rare pregnancy condition programs babies to become overweight in later life 2Rare pregnancy condition programs babies to become overweight in later life 3
Request Info...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
...
Hybridization Buffer 3.6 ml...
Biology Products: